Time to market has never been as critical as with the search for the COVID-19 vaccine. Moderna Therapeutics (MRNA), who in December 2018, led the largest biotech IPO in history, is in that race against the clock, deploying a novel technology, messenger RNA. Messenger RNA is also the technology of the company’s platform approach to the development of treatments for potentially 20 diseases and in theory applicable to many more. Being the CEO of a life sciences company working on a technology that has not previously led to an approved vaccine or drug, requires an extra dose of "boldness, curiosity, and collaboration", in the words of Stéphane Bancel. Where is Moderna in the race to market the vaccine? How could the vaccine be distributed? How did his own education as an engineer and an MBA prepare him for this challenge? How does Stéphane Bancel explain the science behind their products? How does the company empower its people and build a culture?
Stéphane Bancel has served as Chief Executive Officer of Moderna Therapeutics since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, he served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, Stéphane Bancel served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, he served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Stéphane Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Stéphane Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
In this episode:
In this episode, Denise Silber, host of HAE Invites, interviews the CEO of Moderna Therapeutics (MRNA), one of the most strategic and observed life science companies of the COVID-19 crisis. In December 2018, Moderna became the largest biotech IPO in history. Now in 2020, they are called upon to do what has never been done before, to accelerate the development of a vaccine for a new disease. Join Denise as she speaks with Stéphane Bancel, the founding Chief Executive Officer of this Cambridge, Massachusetts research-based firm, whose pioneering messenger RNA (mRNA) technology platform, includes a leading COVID-19 vaccine candidate. How do you manage a company working on such a visible challenge at such a complex time? An engineer and a Harvard MBA, with 25 years in pharma and life sciences, Stéphane Bancel provides HAE Invites podcast series with fascinating insights into the development of the vaccine, the future of drug discovery, lessons learned in leadership, management, and entrepreneurship in a context of high uncertainty, and his Harvard connection.